Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J. Landovitz, Sheldon D. Fields, Deborah Donnell et al.|New England Journal of Medicine|2021Cited by 847
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 AcquisitionLawrence Corey, Myron S. Cohen, Allan C. deCamp et al.|New England Journal of Medicine|2021Cited by 540
Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing TitersEshan U. Patel, Oliver Laeyendecker, Evan M. Bloch et al.|Journal of Clinical Microbiology|2020Cited by 198
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083Mark A. Marzinke, Susan H. Eshleman, Beatriz Grinsztejn et al.|The Journal of Infectious Diseases|2021Cited by 129